Experts comment the JUPITER trial in the latest NEJM issue
Experts around the globe comment the JUPITER trial in the correspondence section of the March 5, 2009 issue of the NEJM. I collect here some of the most relevant and interesting correspondence to the editor.
“JUPITER is notable for the unacknowledged exclusion of a population that may be at increased risk for dose-related adverse effects of rosuvastatin.”
Adriane Fugh-Berman, M.D.
Georgetown University Medical Center
Washington, DC 20007
ajf29@georgetown.edu
“JUPITER was stopped early, after a median follow-up of 1.9 years. The number of patients who would need to be treated for 2 years to prevent the occurrence of one primary end point was 95. Ridker et al. extrapolate these results by a projection over a 5-year treatment period. This estimation should be viewed critically, since the study has most of the characteristics of a truncated trial”.
“The majority of randomized clinical trials that are stopped early because of an observed benefit of the treatment under investigation are industry-funded drug trials that are stopped at the first interim analysis, with the results published in a high-impact medical journal”.Luc A. Pierard, M.D., Ph.D.
University Hospital Sart Tilman
B 4000 Liege, Belgium
lpierard@chu.ulg.ac.be
Read the correspondence section for further comments.
Related links:
- The JUPITER trial: Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. NEJM, November 2008.
- Expanding the Orbit of Primary Prevention — Moving beyond JUPITER
- Breaking News: The Jupiter Trial. Clinical Correlations: The NYU Internal Medicine Blog
